Communique for the permanent re-instatement of telehealth phone consultations
COSA guidelines for fertility preservation for people with cancer
The COSA Fertility Preservation Guidelines Working Group has developed these guidelines to assist health professionals discuss and manage fertility preservation for people with cancer in Australia.
COSA Annual Report 2021
Preventing Australians from slipping through the NET: The first National Action Plan for Neuroendocrine Tumours (2022-2027)
Preventing Australians from slipping through the NET: The first National Action Plan for Neuroendocrine Tumours (NETs) 2022-2027 (published November 2021)
NeuroEndocrine Cancer Australia's National Action Plan has been developed in collaboration with key stakeholders, patients, the consumer advisory group, Centres of Excellence and leading Healthcare Specialists across Australia to develop a clear strategy for better neuroendocrine cancer education, treatment and support.
Medical Oncology Group of Australia Position Statement on COVID-19 vaccination in patients with solid tumours
Medical Oncology Group of Australia Position Statement on COVID-19 vaccination in patients with solid tumours (version 9 published 17 October 2021)
This position statement has been developed for cancer clinicians and other healthcare professionals caring for people with cancer. The COVID-19 pandemic is constantly evolving and the position statement may be updated with emergence of new evidence. Clinicians should remain cognisant that data is rapidly changing around current vaccines and newer agents, both in terms of positive and negative effects. This statement has been endorsed by COSA.
eviQ provides protocols and guidelines for Indication for Genetic Testing and the Management of Familiar Cancer Syndromes
Neuroendocrine Tumours Group Chair